biote Corp. (BTMD) Stock Analysis and Metrics

Biote

NASDAQ: BTMD

$2.43 ▲ +0.05 (+2.31%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap5,970.00

P/E0.00

P/S0.00

Div. Yield240.87

ROIC (Qtr)0.00

Total Debt (Qtr)100.68 Mn

Revenue Growth (1y) (Qtr)-8.28

Add ratio to table…

About

biote Corp. operates a high growth practice building business in the hormone optimization space. The company provides Biote certified practitioners with an end to end platform that includes education, training and certification, practice management software, inventory management software, information on hormone replacement therapy products, digital and point of care marketing support, and a line of Biote branded dietary supplements. By charging fees for the Biote Method and selling its branded supplements, biote Corp. enables clinicians to establish and grow hormone optimization practices using a cash pay model that minimizes reliance on insurance reimbursement. biote Corp. functions similarly to a franchise model, supplying the necessary components for practitioners to build, launch and sustain a hormone optimization program within their existing clinics.

biote Corp. generates revenue primarily from two sources: fees charged to Biote partner clinics for the Biote Method and sales of Biote branded dietary supplements. The Biote Method fees cover education, training, re training, practice management support, inventory management services and the pass through cost of hormone pellets that clinicians may choose to provide as part of treatment. In 2025 service fees accounted for about 71% of total revenue while supplement sales represented roughly 22%, with the company reporting total revenue of $192.2 million for the year ended December 31, 2025 compared with $197.2 million for the prior year. Net income was $31.6 million for the year ended December 31, 2025 versus $0.05 million for the year ended December 31, 2024, reflecting improved profitability.

The company operates through the following segments.

• Biote's operating segment: This segment encompasses the Biote Method practice building platform, including education, training and certification, practice management software, inventory management software, clinical decision support, and the sale of Biote branded dietary supplements, which together support clinicians in delivering hormone optimization therapy and related wellness products.

biote Corp. holds a leading position in the practice building market for hormone optimization, competing with companies such as Evexias Health Solutions, SottoPelle, Pellecome LLC and Purepell. The U. S. hormone replacement therapy market exceeded $7 billion in 2020 and is projected to grow at approximately 7% annually through 2026, providing a sizable opportunity for bioidentical hormone therapy services. The company differentiates itself through a proprietary end to end platform that combines education, training, practice management tools, inventory management and clinical decision support with a line of Biote branded supplements, allowing practitioners to offer a cash based, high margin service. Strong brand recognition among practitioners, a practitioner retention rate above 91%, a network of over 9,200 Biote certified practitioners in more than 5,300 clinics, and proven profitability with $31.6 million net income in 2025 reinforce its competitive advantages.

biote Corp. serves Biote certified practitioners who operate clinics across specialties such as obstetrics and gynecology, family and general practice, urology and internal medicine. Approximately 70% of the company's customer base consists of these specialty practices, while the remaining patients receive hormone optimization therapy and Biote branded supplements through their treating clinicians. As of December 31, 2025, over 9,200 Biote certified practitioners were contracted, roughly 65% of their clinics offered Biote branded supplements, and the average supplement volume per practice was about $7,900.

Investment Thesis

▲ Bull case

The company’s strategic expansion of its sales force is positioned to unlock delayed revenue acceleration that the market has not yet priced in. Management added more than 25 new representatives in the first quarter bringing the team toward its target of 120, and these hires are already receiving full training and territory assignments. Historically, a new sales representative requires a ramp‑up period of three to six months before contributing meaningfully to bookings, which aligns with the timeline for a visible impact in the third quarter. The concurrent increase in practitioner training, with over 200 new providers certified in Q1 representing a 16.5% rise year over year, creates a fresh pipeline of demand that will begin to convert after the typical six‑month latency period. As these dual forces mature, the company expects a return to procedure revenue growth in the second half of 2026, supporting the unchanged full‑year guidance of revenue above $190 million and adjusted EBITDA above $38 million.
The dietary supplement line is emerging as a higher‑margin, scalable growth engine that could reduce reliance on the procedural business and improve overall profitability. Supplement sales jumped 19.1% to $11 million in the first quarter, driven principally by the expanding e‑commerce channel that bypasses traditional clinic‑based friction. Management noted that the supplement business is forecast to grow at a mid‑ to high‑single‑digit rate for the full year, a trajectory that could steadily increase its share of total revenue from the current ~24% toward 30% or more by year‑end. Because supplement production involves fewer regulatory hurdles and lower variable costs than hormone pellet manufacturing, gross margins in this segment are likely to remain above the corporate average, thereby lifting consolidated profitability. If the e‑commerce momentum continues, the supplement division could act as a buffer against any procedural volatility and provide a clear path to sustained earnings expansion.
Leadership continuity following the CEO transition may actually enhance operational focus and reduce execution risk, a factor that the market appears to be overlooking. Bob Peterson, who will assume the interim CEO role on June 8, 2026, has already served as CFO and was recently promoted to Chief Business Officer, giving him deep insight into financial controls, operational scaling, and the integration of Asteria Health. His internal promotion minimizes the typical onboarding lag associated with an external hire and preserves institutional knowledge of ongoing initiatives such as the sales force expansion and supply chain normalization. The Board’s explicit confidence in Peterson, coupled with the retention of Executive Chairman Marc Beer, suggests a stable governance environment that can maintain strategic momentum. This seamless leadership shift could enable faster decision‑making on capital allocation, cost control, and growth investments, thereby supporting the achievement of the 2026 financial targets.
Supply chain remediation efforts are advancing more quickly than management’s cautious commentary implies, setting the stage for a margin rebound that could surprise investors. The company reported that it is adding a second production shift at Asteria Health and leveraging third‑party pharmacy partners to bridge the gap created by the voluntary recall. Peterson noted that the second shift has just recently started and that, within a couple of weeks, the company expects to be in a solid position to rebuild safety stock and resume normal inventory levels. If these actions succeed, gross margin—which fell to 68.9% in Q1 due to recall‑related costs—could recover toward the historical range of the low‑to‑mid 70s% by the third quarter. A margin improvement of even two or three percentage points, applied to a revenue base approaching $190 million, would generate meaningful incremental earnings and bolster the outlook for adjusted EBITDA beyond the current guidance.
The earn‑out liability volatility that has historically inflated net income may be declining, providing a cleaner view of underlying operational performance and reducing earnings uncertainty. In Q1 2026 the gain from changes in fair value of earn‑out liabilities was $2.1 million, markedly lower than the $10.7 million gain in the same period of 2025. As the earn‑out approaches its settlement date, future fluctuations in this non‑operating item are expected to diminish, making GAAP net income more reflective of core business results. This transition will allow investors to assess the company’s true profitability trends without the noise of large, unpredictable fair‑value adjustments. A clearer earnings picture could lead to a re‑rating of the stock based on sustainable operating performance rather than transient accounting gains.

The company’s strategic expansion of its sales force is positioned to unlock delayed revenue acceleration that the market has not yet priced in. Management added more than 25 new representatives in the first quarter bringing the team toward its target of 120, and these hires are already receiving full training and territory assignments. Historically, a new sales representative requires a ramp‑up period of three to six months before contributing meaningfully to bookings, which aligns with the timeline for a visible impact in the third quarter. The concurrent increase in practitioner training, with over 200 new providers certified in Q1 representing a 16.5% rise year over year, creates a fresh pipeline of demand that will begin to convert after the typical six‑month latency period. As these dual forces mature, the company expects a return to procedure revenue growth in the second half of 2026, supporting the unchanged full‑year guidance of revenue above $190 million and adjusted EBITDA above $38 million.
The dietary supplement line is emerging as a higher‑margin, scalable growth engine that could reduce reliance on the procedural business and improve overall profitability. Supplement sales jumped 19.1% to $11 million in the first quarter, driven principally by the expanding e‑commerce channel that bypasses traditional clinic‑based friction. Management noted that the supplement business is forecast to grow at a mid‑ to high‑single‑digit rate for the full year, a trajectory that could steadily increase its share of total revenue from the current ~24% toward 30% or more by year‑end. Because supplement production involves fewer regulatory hurdles and lower variable costs than hormone pellet manufacturing, gross margins in this segment are likely to remain above the corporate average, thereby lifting consolidated profitability. If the e‑commerce momentum continues, the supplement division could act as a buffer against any procedural volatility and provide a clear path to sustained earnings expansion.
Leadership continuity following the CEO transition may actually enhance operational focus and reduce execution risk, a factor that the market appears to be overlooking. Bob Peterson, who will assume the interim CEO role on June 8, 2026, has already served as CFO and was recently promoted to Chief Business Officer, giving him deep insight into financial controls, operational scaling, and the integration of Asteria Health. His internal promotion minimizes the typical onboarding lag associated with an external hire and preserves institutional knowledge of ongoing initiatives such as the sales force expansion and supply chain normalization. The Board’s explicit confidence in Peterson, coupled with the retention of Executive Chairman Marc Beer, suggests a stable governance environment that can maintain strategic momentum. This seamless leadership shift could enable faster decision‑making on capital allocation, cost control, and growth investments, thereby supporting the achievement of the 2026 financial targets.
Supply chain remediation efforts are advancing more quickly than management’s cautious commentary implies, setting the stage for a margin rebound that could surprise investors. The company reported that it is adding a second production shift at Asteria Health and leveraging third‑party pharmacy partners to bridge the gap created by the voluntary recall. Peterson noted that the second shift has just recently started and that, within a couple of weeks, the company expects to be in a solid position to rebuild safety stock and resume normal inventory levels. If these actions succeed, gross margin—which fell to 68.9% in Q1 due to recall‑related costs—could recover toward the historical range of the low‑to‑mid 70s% by the third quarter. A margin improvement of even two or three percentage points, applied to a revenue base approaching $190 million, would generate meaningful incremental earnings and bolster the outlook for adjusted EBITDA beyond the current guidance.
The earn‑out liability volatility that has historically inflated net income may be declining, providing a cleaner view of underlying operational performance and reducing earnings uncertainty. In Q1 2026 the gain from changes in fair value of earn‑out liabilities was $2.1 million, markedly lower than the $10.7 million gain in the same period of 2025. As the earn‑out approaches its settlement date, future fluctuations in this non‑operating item are expected to diminish, making GAAP net income more reflective of core business results. This transition will allow investors to assess the company’s true profitability trends without the noise of large, unpredictable fair‑value adjustments. A clearer earnings picture could lead to a re‑rating of the stock based on sustainable operating performance rather than transient accounting gains.

▼ Bear case

The voluntary recall of hormone pellets may represent a more structural supply constraint than management admits, posing a lingering risk to procedure volumes and gross margin. Although the company frames the issue as temporary, it acknowledged that more than 80% of patients are women and that estrogen and estradiol pellets are especially difficult to manufacture at scale, a limitation shared across the industry. The reliance on third‑party partners to fill the gap has already lowered the proportion of internally produced pellets from over 50% in 2025 to roughly 30% in Q1, a shift that could persist if Asteria cannot quickly attain full capacity. Ongoing dependence on external suppliers introduces cost variability and potential quality control challenges, which could keep gross margin depressed well beyond the second quarter if the second shift at Asteria faces delays or regulatory hurdles. This structural supply vulnerability could undermine the anticipated procedure revenue rebound in the second half of 2026.
The rapid expansion of the sales force and practitioner training may be generating superficial activity without translating into durable revenue growth, a risk that management’s optimistic commentary does not fully address. While the company trained over 200 new practitioners in Q1, the typical six‑month lag before these providers begin to contribute meaningfully means that any revenue impact will not appear until late 2023 or early 2024, well beyond the current fiscal year. Moreover, the increase in sales representatives to 120 may be outpacing the addressable market for new clinics, leading to diminishing returns on additional headcount and higher selling, general and administrative expenses without commensurate top‑line gains. If the market for hormone optimization services is becoming saturated, the incremental yield from these investments could be lower than projected, pressuring operating leverage and keeping adjusted EBITDA margins below the targeted 19.4% level.
Leadership transition uncertainty could disrupt execution momentum despite the apparent continuity suggested by the internal promotion of Bob Peterson. The Board has retained an executive search firm to identify a permanent CFO, indicating that the current CFO‑to‑CEO shift may be temporary and that a new finance chief could still be brought in mid‑year. Such a change could create ambiguity around capital allocation priorities, especially regarding the ongoing investment in Asteria Health’s vertical integration and potential future acquisitions. Furthermore, the departure of CEO Bret Christensen, who has been the public face of the company’s growth narrative, might affect morale among the field sales team and key practitioner relationships, potentially slowing the adoption of newly trained providers. Any disruption in leadership cohesion could impede the realization of the expected second‑half rebound in procedure revenue.
Dietary supplement growth, while impressive in the short term, may be vulnerable to market saturation and intensifying competition that could curb its long‑term contribution. The 19.1% increase in supplement revenue was driven largely by the e‑commerce channel, which is easily replicable by both existing players and new entrants offering similar wellness products. Management’s guidance of mid‑ to high‑single‑digit supplement growth for the full year assumes that the current traction will persist, but does not address potential pricing pressure, increased marketing costs, or regulatory scrutiny that could arise as the category expands. If supplement margins erode or growth decelerates faster than anticipated, the company’s overall revenue mix could shift back toward the lower‑margin procedural business, weighing on consolidated profitability and making the adjusted EBITDA target of greater than $38 million more difficult to achieve.
The company’s leverage profile and interest expense present a financial risk that could limit flexibility if operating performance falters, a factor that received minimal emphasis in the earnings call. As of March 31, 2026, the term loan balance stood at approximately $100 million, with interest expense near $2 million for the quarter, representing a non‑trivial drag on earnings. Should revenue recovery be slower than expected, the fixed interest obligation could constrain free cash flow and limit the ability to reinvest in growth initiatives such as sales force expansion or supply chain upgrades. Additionally, the outstanding revolving credit facility of $5 million remains available but drawing on it would increase leverage and potentially trigger covenant concerns. In a scenario where procedure revenue does not rebound as forecast, the debt burden could amplify downside risk to net income and constrain the company’s capacity to pursue strategic options.

The voluntary recall of hormone pellets may represent a more structural supply constraint than management admits, posing a lingering risk to procedure volumes and gross margin. Although the company frames the issue as temporary, it acknowledged that more than 80% of patients are women and that estrogen and estradiol pellets are especially difficult to manufacture at scale, a limitation shared across the industry. The reliance on third‑party partners to fill the gap has already lowered the proportion of internally produced pellets from over 50% in 2025 to roughly 30% in Q1, a shift that could persist if Asteria cannot quickly attain full capacity. Ongoing dependence on external suppliers introduces cost variability and potential quality control challenges, which could keep gross margin depressed well beyond the second quarter if the second shift at Asteria faces delays or regulatory hurdles. This structural supply vulnerability could undermine the anticipated procedure revenue rebound in the second half of 2026.
The rapid expansion of the sales force and practitioner training may be generating superficial activity without translating into durable revenue growth, a risk that management’s optimistic commentary does not fully address. While the company trained over 200 new practitioners in Q1, the typical six‑month lag before these providers begin to contribute meaningfully means that any revenue impact will not appear until late 2023 or early 2024, well beyond the current fiscal year. Moreover, the increase in sales representatives to 120 may be outpacing the addressable market for new clinics, leading to diminishing returns on additional headcount and higher selling, general and administrative expenses without commensurate top‑line gains. If the market for hormone optimization services is becoming saturated, the incremental yield from these investments could be lower than projected, pressuring operating leverage and keeping adjusted EBITDA margins below the targeted 19.4% level.
Leadership transition uncertainty could disrupt execution momentum despite the apparent continuity suggested by the internal promotion of Bob Peterson. The Board has retained an executive search firm to identify a permanent CFO, indicating that the current CFO‑to‑CEO shift may be temporary and that a new finance chief could still be brought in mid‑year. Such a change could create ambiguity around capital allocation priorities, especially regarding the ongoing investment in Asteria Health’s vertical integration and potential future acquisitions. Furthermore, the departure of CEO Bret Christensen, who has been the public face of the company’s growth narrative, might affect morale among the field sales team and key practitioner relationships, potentially slowing the adoption of newly trained providers. Any disruption in leadership cohesion could impede the realization of the expected second‑half rebound in procedure revenue.
Dietary supplement growth, while impressive in the short term, may be vulnerable to market saturation and intensifying competition that could curb its long‑term contribution. The 19.1% increase in supplement revenue was driven largely by the e‑commerce channel, which is easily replicable by both existing players and new entrants offering similar wellness products. Management’s guidance of mid‑ to high‑single‑digit supplement growth for the full year assumes that the current traction will persist, but does not address potential pricing pressure, increased marketing costs, or regulatory scrutiny that could arise as the category expands. If supplement margins erode or growth decelerates faster than anticipated, the company’s overall revenue mix could shift back toward the lower‑margin procedural business, weighing on consolidated profitability and making the adjusted EBITDA target of greater than $38 million more difficult to achieve.
The company’s leverage profile and interest expense present a financial risk that could limit flexibility if operating performance falters, a factor that received minimal emphasis in the earnings call. As of March 31, 2026, the term loan balance stood at approximately $100 million, with interest expense near $2 million for the quarter, representing a non‑trivial drag on earnings. Should revenue recovery be slower than expected, the fixed interest obligation could constrain free cash flow and limit the ability to reinvest in growth initiatives such as sales force expansion or supply chain upgrades. Additionally, the outstanding revolving credit facility of $5 million remains available but drawing on it would increase leverage and potentially trigger covenant concerns. In a scenario where procedure revenue does not rebound as forecast, the debt burden could amplify downside risk to net income and constrain the company’s capacity to pursue strategic options.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password